PAOG Expects To Soon Launch 3rd CBD Nutraceutical Adding To 2021 Revenue Potential
PAO Group, Inc. (OTC Pink: PAOG) announced plans to release a third CBD nutraceutical product by year-end 2021, following the launch of its first two products, RelaxRX CBD and RehabRX CBD. The company confirmed a second production run for these products due to strong market response and has already shipped them to its distribution partner, North American Cannabis Holdings, Inc. PAOG aims to generate revenue in Q4 2021, leveraging its acquired extraction technology. Additionally, the company is developing a line of CBD women’s health products in collaboration with Alkame Holdings, Inc.
- Introduction of a third CBD nutraceutical product by year-end 2021.
- Strong initial response leading to a second production run of existing products.
- First shipments made to distribution partner, indicating early demand.
- Expected revenue generation in Q4 2021.
- Plans for future product launches to enhance sales potential.
- None.
Sandusky, OH, Nov. 09, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company is on track to introduce yet a third CBD nutraceutical product by year end.
PAOG recently announced the launch of its first two CBD nutraceutical products, RelaxRX CBD, a sleep aid, and RehabRX CBD, a salve.
PAOG has also announced initiating a second production run of the first two CBD nutraceutical products based on the initial response to the marketing launch.
PAOG has confirmed shipping its first and second CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). Even before the product has been set up for sale online at www.USMJ.com, inquires for the product have indicated a rapid sellout.
Last year, the company acquired intellectual property form Nouveau Life Pharmaceuticals (OTC Pink: NOUV) derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property.
PAOG is on track to realize its first revenue this year, starting in Q4 2021, since acquiring the extraction technology.
PAOG expects revenue to grow rapidly following its first three CBD nutraceutical product launches as the company has follow on products lined up to follow these products adding to overall sales potential.
PAOG has also initiated development of a new CBD line of women’s health products, working closely with Alkame Holdings, Inc. (OTC Pink: ALKM) for special packaging requirements.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
(888) 979-2675
info@pao.group
FAQ
What are PAO Group's new product launches for 2021?
When does PAO Group expect to start generating revenue?
Who is PAO Group's distribution partner for CBD products?
What is PAO Group's focus in product development?
